These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

123 related articles for article (PubMed ID: 33347025)

  • 1. Finding Early Improvement Threshold to Predict Response After 8 Weeks of Treatment Using Risperidone in First-Episode Psychosis.
    Subeesh V; Maheswari E; Singh H; Neha R; Mazhar F
    J Clin Psychopharmacol; 2021 Jan/Feb 01; 41(1):58-61. PubMed ID: 33347025
    [TBL] [Abstract][Full Text] [Related]  

  • 2. An early improvement threshold to predict response and remission in first-episode schizophrenia.
    Schennach-Wolff R; Seemüller FH; Mayr A; Maier W; Klingberg S; Heuser I; Klosterkötter J; Gastpar M; Häfner H; Sauer H; Schneider F; Gaebel W; Jäger M; Möller HJ; Riedel M
    Br J Psychiatry; 2010 Jun; 196(6):460-6. PubMed ID: 20513856
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Oral versus injectable antipsychotic treatment in early psychosis: post hoc comparison of two studies.
    Emsley R; Oosthuizen P; Koen L; Niehaus DJ; Medori R; Rabinowitz J
    Clin Ther; 2008 Dec; 30(12):2378-86. PubMed ID: 19167596
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Early prediction of clinical response in first episode schizophrenia (FES) patients receiving olanzapine.
    Subeesh V; Maheswari E; Singh H; Saraswathy GR; Reddy N; Chiranjeevi P
    Int J Psychiatry Clin Pract; 2020 Sep; 24(3):309-314. PubMed ID: 32338556
    [No Abstract]   [Full Text] [Related]  

  • 5. Efficacy of iloperidone in the short-term treatment of schizophrenia: a post hoc analysis of pooled patient data from four phase III, placebo- and active-controlled trials.
    Citrome L; Meng X; Hochfeld M; Stahl SM
    Hum Psychopharmacol; 2012 Jan; 27(1):24-32. PubMed ID: 22161738
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Assessment of strategies for switching patients from olanzapine to risperidone: a randomized, open-label, rater-blinded study.
    Ganguli R; Brar JS; Mahmoud R; Berry SA; Pandina GJ
    BMC Med; 2008 Jun; 6():17. PubMed ID: 18590519
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A prospective, open-label study to evaluate symptomatic remission in schizophrenia with risperidone long-acting injectable in Korea.
    Lee NY; Kim SH; Cho SJ; Chung YC; Jung IK; Kim CY; Kim DH; Lee DG; Lee YH; Lim WJ; Na YS; Shin SE; Woo JM; Yoon JS; Yoon BH; Ahn YM; Kim YS
    Int Clin Psychopharmacol; 2014 Sep; 29(5):279-87. PubMed ID: 24583566
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Early response to antipsychotic drug therapy as a clinical marker of subsequent response in the treatment of schizophrenia.
    Kinon BJ; Chen L; Ascher-Svanum H; Stauffer VL; Kollack-Walker S; Zhou W; Kapur S; Kane JM
    Neuropsychopharmacology; 2010 Jan; 35(2):581-90. PubMed ID: 19890258
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Time to treatment response in first-episode schizophrenia: should acute treatment trials last several months?
    Gallego JA; Robinson DG; Sevy SM; Napolitano B; McCormack J; Lesser ML; Kane JM
    J Clin Psychiatry; 2011 Dec; 72(12):1691-6. PubMed ID: 21939612
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A trial of low doses of risperidone in the treatment of patients with first-episode schizophrenia, schizophreniform disorder, or schizoaffective disorder.
    Huq ZU;
    J Clin Psychopharmacol; 2004 Apr; 24(2):220-4. PubMed ID: 15206670
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Rationale for the use of long-acting injectable risperidone: a survey of French psychiatrists].
    Misdrahi D; Delgado A; Bouju S; Comet D; Chiariny JF
    Encephale; 2013 May; 39 Suppl 1():S8-14. PubMed ID: 23541914
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Long-acting injectable risperidone: naturalistic study in three hospitals in Aquitaine].
    Raignoux C; Dusouchet T; Bret P; Queuille E; Biscay ML; Caron J; Bret MC
    Encephale; 2007 Dec; 33(6):973-81. PubMed ID: 18789790
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Risperidone in the treatment of first episode psychosis.
    Yap HL; Mahendran R; Lim D; Liow PH; Lee A; Phang S; Tiong A
    Singapore Med J; 2001 Apr; 42(4):170-3. PubMed ID: 11465317
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Switching patients with stable schizophrenia or schizoaffective disorder from olanzapine to risperidone long-acting injectable.
    Rosa F; Schreiner A; Thomas P; Sherif T
    Clin Drug Investig; 2012 Apr; 32(4):267-79. PubMed ID: 22339430
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Intranasal oxytocin as an adjunct to risperidone in patients with schizophrenia : an 8-week, randomized, double-blind, placebo-controlled study.
    Modabbernia A; Rezaei F; Salehi B; Jafarinia M; Ashrafi M; Tabrizi M; Hosseini SM; Tajdini M; Ghaleiha A; Akhondzadeh S
    CNS Drugs; 2013 Jan; 27(1):57-65. PubMed ID: 23233269
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy and tolerability of ziprasidone versus risperidone in patients with acute exacerbation of schizophrenia or schizoaffective disorder: an 8-week, double-blind, multicenter trial.
    Addington DE; Pantelis C; Dineen M; Benattia I; Romano SJ
    J Clin Psychiatry; 2004 Dec; 65(12):1624-33. PubMed ID: 15641867
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A long-term, multicenter, open-label study of risperidone in elderly patients with psychosis. On behalf of the Risperidone Working Group.
    Davidson M; Harvey PD; Vervarcke J; Gagiano CA; De Hooge JD; Bray G; Dose M; Barak Y; Haushofer M
    Int J Geriatr Psychiatry; 2000 Jun; 15(6):506-14. PubMed ID: 10861916
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Altered Antioxidant Defenses in Drug-Naive First Episode Patients with Schizophrenia Are Associated with Poor Treatment Response to Risperidone: 12-Week Results from a Prospective Longitudinal Study.
    Li XR; Xiu MH; Guan XN; Wang YC; Wang J; Leung E; Zhang XY
    Neurotherapeutics; 2021 Apr; 18(2):1316-1324. PubMed ID: 33791970
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Remission in schizophrenia: Results from a 1-year study of long-acting risperidone injection.
    Lasser RA; Bossie CA; Gharabawi GM; Kane JM
    Schizophr Res; 2005 Sep; 77(2-3):215-27. PubMed ID: 15908183
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Quetiapine extended release versus aripiprazole in children and adolescents with first-episode psychosis: the multicentre, double-blind, randomised tolerability and efficacy of antipsychotics (TEA) trial.
    Pagsberg AK; Jeppesen P; Klauber DG; Jensen KG; Rudå D; Stentebjerg-Olesen M; Jantzen P; Rasmussen S; Saldeen EA; Lauritsen MG; Bilenberg N; Stenstrøm AD; Nyvang L; Madsen S; Werge TM; Lange T; Gluud C; Skoog M; Winkel P; Jepsen JRM; Fagerlund B; Correll CU; Fink-Jensen A
    Lancet Psychiatry; 2017 Aug; 4(8):605-618. PubMed ID: 28599949
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.